ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Antimicrobial Chemotherapy

• Publication date

  2016-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jac/dkw158PMID 27550993
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients.

  2016cited by this paper
• ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.

  2016cited by this paper
• Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma

  2016cited by this paper
• ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.

  2016cited by this paper
• New therapeutic strategies for invasive aspergillosis in the era of azole resistance: how should the prevalence of azole resistance be defined?

  2016cited by this paper
• Impact of Initial Ventilatory Strategy in Hematological Patients With Acute Respiratory Failure: A Systematic Review and Meta-Analysis*

  2016cited by this paper
• Effect of Noninvasive Ventilation vs Oxygen Therapy on Mortality Among Immunocompromised Patients With Acute Respiratory Failure: A Randomized Clinical Trial.

  2015cited by this paper
• Managing critically Ill hematology patients: Time to think differently.

  2015cited by this paper
• Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection.

  2015cited by this paper
• Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV infection.

  2015cited by this paper
• Acute respiratory failure in patients with hematological malignancies: outcomes according to initial ventilation strategy. A groupe de recherche respiratoire en réanimation onco-hématologique (Grrr-OH) study

  2015cited by this paper
• Prognostic factors of Pneumocystis jirovecii pneumonia in patients without HIV infection.

  2014cited by this paper
• [Pneumocystis jiroveci pneumonia: comparative study of cases in HIV-infected patients and immunocompromised non-HIV-infected patients].

  2014cited by this paper
• Outcomes of Pneumocystis pneumonia with respiratory failure in HIV-negative patients.

  2014cited by this paper
• Acute respiratory distress syndrome in patients with malignancies

  2014cited by this paper
• Serum Peak Sulfamethoxazole Concentrations Demonstrate Difficulty in Achieving a Target Range: A Retrospective Cohort Study

  2014cited by this paper
• Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients.

  2014cited by this paper
• Cotrimoxazole - optimal dosing in the critically ill

  2014cited by this paper
• Pneumocystis jirovecii Pneumonia in Patients with or without AIDS, France

  2014cited by this paper
• Clinical outcome and predictors of survival in patients with pneumocystis jirovecii pneumonia – results of a tertiary referral centre

  2014cited by this paper
• Pneumocystis Pneumonia in HIV-Infected and Immunocompromised Non-HIV Infected Patients: A Retrospective Study of Two Centers in China

  2014cited by this paper
• Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014

  2014cited by this paper
• Características clínicas, diagnósticas y pronósticas de pacientes con neumonía por Pneumocystis jiroveci en individuos infectados por virus de inmunodeficiencia humana e individuos inmunocomprometidos por otra etiología

  2014cited by this paper
• Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals.

  2014cited by this paper
• Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients.

  2014cited by this paper
• Therapeutic Potential of Caspofungin Combined with Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia: A Pilot Study in Mice

  2013cited by this paper
• Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium--a groupe de recherche respiratoire en réanimation onco-hématologique study.

  2013cited by this paper
• Dihydropteroate synthase mutations in Pneumocystis pneumonia: impact of applying different definitions of prophylaxis, mortality endpoints and mutant in a single cohort.

  2013cited by this paper
• Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia

  2013cited by this paper
• Is caspofungin really an effective treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients without human immunodeficiency virus infection? Experiences at a single center and a literature review

  2013cited by this paper
• Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure

  2013cited by this paper
• Combination of caspofungin and low‐dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients

  2013cited by this paper
• Intensive care unit management of patients with newly diagnosed acute myeloid leukemia with no organ failure

  2012cited by this paper
• Ventilatory support in critically ill hematology patients with respiratory failure

  2012cited by this paper
• Pneumocystis pneumonia in hospitalized patients: a detailed examination of symptoms, management, and outcomes in human immunodeficiency virus (HIV)‐infected and HIV‐uninfected persons

  2012cited by this paper
• Risk factors for the development of acute lung injury in patients with infectious pneumonia

  2012cited by this paper
• Non-HIV Pneumocystis pneumonia: do conventional community-acquired pneumonia guidelines under estimate its severity?

  2012cited by this paper
• HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients.

  2012cited by this paper
• ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT).

  2012cited by this paper
• Early diagnosis and treatment are crucial for the survival of Pneumocystis pneumonia patients without human immunodeficiency virus infection

  2012cited by this paper
• An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.

  2011cited by this paper
• β-d-Glucan kinetics for the assessment of treatment response in Pneumocystis jirovecii pneumonia.

  2011cited by this paper
• Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes

  2011cited by this paper
• Outcomes of Moderate-to-Severe Pneumocystis Pneumonia Treated with Adjunctive Steroid in Non-HIV-Infected Patients

  2011cited by this paper
• Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience

  2011cited by this paper
• Update on the diagnosis and treatment of Pneumocystis pneumonia

  2011cited by this paper
• [Pneumocystis jirovecii pneumonia in non-HIV infected patients: a study of 41 cases].

  2011cited by this paper
• Noninvasive ventilation in patients with malignancies and hypoxemic acute respiratory failure: a still pending question.

  2010cited by this paper
• Early Antiretroviral Therapy Reduces AIDS Progression/Death in Individuals with Acute Opportunistic Infections: A Multicenter Randomized Strategy Trial

  2009cited by this paper
• Clindamycin-primaquine versus pentamidine for the second-line treatment of pneumocystis pneumonia

  2009cited by this paper
• Acute respiratory failure due to Pneumocystis pneumonia: outcome and prognostic factors.

  2009cited by this paper
• Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study.

  2009cited by this paper
• Pneumocystis jiroveci pneumonia in a patient with Wegener’s granulomatosis treated efficiently with caspofungin

  2008cited by this paper
• Predictors of noninvasive ventilation failure in patients with hematologic malignancy and acute respiratory failure*

  2008cited by this paper
• Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection

  2008cited by this paper
• Efficacy of Caspofungin Addition to Trimethoprim-Sulfamethoxazole Treatment for Severe Pneumocystis Pneumonia in Solid Organ Transplant Recipients

  2007cited by this paper
• Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: A retrospective study 2002–2004

  2007cited by this paper
• Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients.

  2007cited by this paper
• Pneumocystis pneumonia--a retrospective study 1991-2001 in Gothenburg, Sweden.

  2006cited by this paper
• Influence of type of cancer and hematopoietic stem cell transplantation on clinical presentation of Pneumocystis jiroveci pneumonia in cancer patients

  2006cited by this paper
• Progression of Pneumocystis jiroveci pneumonia in patients receiving echinocandin therapy.

  2006cited by this paper
• Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation

  2005cited by this paper
• Outcome in noninvasively and invasively ventilated hematologic patients with acute respiratory failure.

  2004cited by this paper
• Incidence and prognostic value of respiratory events in acute leukemia

  2004cited by this paper
• Predictive factors of intensive care unit admission in patients with haematological malignancies and pneumonia

  2004cited by this paper
• Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study.

  2003cited by this paper
• Association between a specific Pneumocystis jiroveci dihydropteroate synthase mutation and failure of pyrimethamine/sulfadoxine prophylaxis in human immunodeficiency virus-positive and -negative patients.

  2003cited by this paper
• Pneumocystis carinii pneumonia in critically ill patients with malignancy: a descriptive study.

  2002cited by this paper
• Analysis of Underlying Diseases and Prognosis Factors Associated with Pneumocystis carinii Pneumonia in Immunocompromised HIV-Negative Patients

  2002cited by this paper
• Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres

  2002cited by this paper
• Noninvasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure.

  2001cited by this paper
• Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study.

  2001cited by this paper
• Permanent declines in pulmonary function following pneumonia in human immunodeficiency virus-infected persons. The Pulmonary Complications of HIV Infection Study Group.

  2000cited by this paper
• Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients.

  1999cited by this paper
• Pneumocystis carinii pneumonia in human immunodeficiency virus (HIV)-positive and HIV-negative immunocompromised patients.

  1999cited by this paper
• Persistence of Pneumocystis carinii after effective treatment of P. carinii pneumonia is not related to relapse or survival among patients infected with human immunodeficiency virus.

  1998cited by this paper
• Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia.

  1998cited by this paper
• The 'hidden' carbapenemase of Aeromonas hydrophila.

  1996cited by this paper
• Comparison of Three Regimens for Treatment of Mild to Moderate Pneumocystis carinii Pneumonia in Patients with AIDS: A Double-Blind, Randomized Trial of Oral Trimethoprim-Sulfamethoxazole, Dapsone-Trimethoprim, and Clindamycin-Primaquine

  1996cited by this paper
• Pneumocystis carinii infection: current treatment and prevention.

  1996cited by this paper
• Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy.

  1996cited by this paper
• Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients

  1995cited by this paper
• Clinical characteristics and outcome of Pneumocystis carinii pneumonia in HIV-infected and otherwise immunosuppressed patients.

  1995cited by this paper
• Intensity of immunosuppressive therapy and the incidence of pneumocystis carinii pneumonitis

  1975cited by this paper
• PNEUMOCYSTIS CARINII INFECTION

  1973cited by this paper

• Reassessing the efficacy and safety of trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia: a retrospective study.

  2026cites this paper
• Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio as prognostic indicators in Pneumocystis jirovecii pneumonia.

  2026cites this paper
• Antifungal treatment strategies in intensive care unit patients

  2026cites this paper
• Risk factors for adverse events associated with trimethoprim-sulfamethoxazole treatment for Pneumocystis pneumonia in non-human immunodeficiency virus-infected patients: a multicenter, retrospective, observational cohort study

  2026cites this paper
• Real-world clinical effectiveness of trimethoprim-sulfamethoxazole for primary prophylaxis of pneumocystis pneumonia in non-hodgkin lymphoma patients treated with rituximab.

  2026cites this paper
• Association between low-dose trimethoprim-sulfamethoxazole blood concentration and clinical outcomes in non-HIV patients with Pneumocystis jirovecii pneumonia: a retrospective cohort study.

  2026cites this paper
• The 2025 EQUAL Pneumocystis Score—an ECMM tool to measure QUALity in Pneumocystis pneumonia management

  2025cites this paper
• Performance of Quantitative PCR to Distinguish Pneumocystis jirovecii Pneumonia From Colonisation in Immunocompromised Patients

  2025cites this paper
• Consecutive non-Aspergillus Fungal Invasive Infections in Chronic Granulomatous Disease: Data from the French National Reference Center for Primary ImmunoDeficiencies and literature review

  2025cites this paper
• Efficacy and Safety of Low-Dose Trimethoprim-Sulfamethoxazole (TMP-SMZ) for the Prevention of Pneumocystis jirovecii pneumonia (PJP) in Non-HIV, Non-Transplant Immunosuppressed Patients: A Real-World Cohort Study

  2025cites this paper
• Evaluation and Clinical Impact of the Combination of Wako® (1,3)-β-D-Glucan in Serum and RT-PCR in Oral Wash for Pneumocystis jirovecii Infection Diagnosis: A Retrospective Cohort Study.

  2025cites this paper
• Population pharmacokinetics and Monte Carlo-based dosing optimization of trimethoprim-sulfamethoxazole

  2025cites this paper
• Pegylated Liposomal Doxorubicin Confers a High Risk for Pneumocystis Jirovecii Pneumonia in Patients With Diffuse Large B-Cell Lymphoma.

  2025cites this paper
• Pneumocystis jirovecii pneumonia in a patient with Mycobacterium intracellulare pulmonary disease: a case report

  2025cites this paper
• Bronkoalveolar Lavaj Örneklerinde Pneumocystis jirovecii Pozitifliği ve Ampirik Tedavi Yaklaşımı

  2025cites this paper
• Pneumocystis pneumonia in older non-HIV-infected patients: a French, multicentre, retrospective, cohort study

  2025cites this paper
• Lymphocyte dynamics as the central mediator in osimertinib-induced CD4+ T-cell depletion, fulminant cytomegalovirus pneumonitis, and progressive pulmonary fibrosis: a case report

  2025cites this paper
• Immune responses of different hosts to Pneumocystis infection

  2025cites this paper
• Pilzinfektionen auf der Intensivstation

  2025cites this paper
• A nomogram-based clinical prediction model for adverse clinical outcomes in non-HIV Pneumocystis jirovecii pneumonia patients

  2025cites this paper
• Case Report: Rapid Progression of Pulmonary Interstitial Fibrosis Combined With Pneumocystis Pneumonia in a Patient With Rheumatoid Arthritis Treated With Tocilizumb

  2025cites this paper
• European guidelines on treatment and supportive measures in chronic neutropenias: A consensus between the European Hematology Association and the EuNet‐INNOCHRON COST Action based on a systematic evidence review

  2025cites this paper
• Association of time-to-treatment with prognosis in pneumocystis pneumonia among immunocompromised patients without HIV infection: a multi-center, retrospective observational cohort study

  2025influential citation
• Evaluation of the Loop-Mediated Isothermal Amplification Assay (LAMP) Eazyplex® Pneumocystis jirovecii

  2025cites this paper
• Duration of systemic antifungal therapy for patients with invasive fungal diseases: A reassessment.

  2025cites this paper
• [Opportunities offered by molecular diagnostics in the management of invasive fungal infections of oncohematological patients].

  2025cites this paper
• Pneumocystis jirovecii pneumonia with use of brentuximab vedotin in treatment-naïve Hodgkin lymphoma

  2025cites this paper
• Bronchoalveolar lavage fluid (BALF): Clinical applications for present and future

  2025cites this paper
• Invasive Fungal Disease After Chimeric Antigen Receptor-T Immunotherapy in Adult and Pediatric Patients

  2025cites this paper
• Pneumocystis Jirovecii Pneumonia in Two Immunosuppressed Non-HIV Infected Patients: A Clinical and Therapeutic Analysis

  2025cites this paper
• Progression of Idiopathic Inflammatory Myopathy with Pneumocystis Jirovecii Pneumonia

  2025cites this paper
• Development and assessment of a mortality risk prediction nomogram model for pneumocystis disease in ICU within 28 days

  2025cites this paper
• Comparison between the Outcomes of Pentamidine and Trimethoprim-Sulfamethoxazole for Pneumocystis Pneumonia in Non-HIV Patients: A Nationwide Japanese Retrospective Cohort Study

  2025cites this paper
• Pneumonia caused by co-infection with Pneumocystis jirovecii and Trichosporon coremiiforme.

  2025cites this paper
• Clinical analysis of Pneumocystis jirovecii pneumonia in children with malignant disease

  2025cites this paper
• 婴儿白血病合并耶氏肺孢子菌肺炎1例并文献复习

  2025cites this paper
• Pneumocystis jirovecii pneumonia in paediatric acute lymphoblastic leukaemia: A report from the multi‐international clinical trial AIEOP‐BFM ALL 2009

  2024cites this paper
• Cutaneous Pneumocystis Jirovecii Infection in an Allogeneic Stem Cell Transplant Recipient

  2024cites this paper
• Computed tomography-based radiomics improves non-invasive diagnosis of Pneumocystis jirovecii pneumonia in non-HIV patients: a retrospective study

  2024cites this paper
• Cytomegalovirus detection is associated with ICU admission in non-AIDS and AIDS patients with Pneumocystis jirovecii pneumonia

  2024cites this paper
• Infections fongiques en réanimation

  2024cites this paper
• A Case of Pneumocystis Pneumonia Developed During Rheumatoid Arthritis Treatment With Methotrexate and Golimumab

  2024cites this paper
• A regimen based on the combination of trimethoprim/sulfamethoxazole with caspofungin and corticosteroids as a first-line therapy for patients with severe non-HIV-related pneumocystis jirovecii pneumonia: a retrospective study in a tertiary hospital

  2024cites this paper
• Risk Factors for Pneumocystis jirovecii Pneumonia in Children With Systemic Lupus Erythematosus Exposed to Prolonged High-Dose Glucocorticoids

  2024cites this paper
• Pneumocystose

  2024cites this paper
• Fungal infections in immunocompromised critically ill patients

  2024cites this paper
• 宏基因组二代测序在异基因造血干细胞移植后耶氏肺孢子菌肺炎诊断中的意义

  2024cites this paper
• Novel antifungals and treatment approaches to tackle resistance and improve outcomes of invasive fungal disease

  2024cites this paper
• Lessons from Multiple Infections Such as Lymphoma Complicated with Pneumocystis Infection: A Case Report

  2024cites this paper
• Pulmonary coinfection by Pneumocystis jirovecii and Aspergillus terreus in an ITP patient after corticosteroid therapy: A case report

  2024cites this paper
• Effectiveness of pulse methylprednisolone in patients with non-human immunodeficiency virus pneumocystis pneumonia: a multicentre, retrospective registry-based cohort study

  2024cites this paper
• 异基因造血干细胞移植后耶氏肺孢子菌肺炎20例临床特征

  2024cites this paper
• Outcomes of low-dose trimethoprim-sulfamethoxazole treatment in patients with non-HIV pneumocystis pneumonia: A nationwide Japanese retrospective cohort study.

  2024cites this paper
• Prognostic analysis of Pneumocystis jirovecii pneumonia in patients with systemic vasculitides: a retrospective cohort study

  2024cites this paper
• Comparison of High-Dose versus Low-Dose Trimethoprim–Sulfamethoxazole for Treating Pneumocystis jirovecii Pneumonia among Hemodialysis Patients: A Nationwide Database Study in Japan

  2024cites this paper
• Use of trimethoprim- sulfamethoxazole for treating Pneumocystis jirovecii pneumonia in a patient with glucose-6-phosphate dehydrogenase deficiency: a case report

  2024cites this paper
• Prognostic Factors of In-hospital Mortality in Patients without Human Immunodeficiency Virus Infection with Pneumocystis Pneumonia: A Retrospective Cohort Study

  2024cites this paper
• Severe Pneumocystis jirovecii pneumonia: time to reassess our practices

  2024cites this paper
• Clinical course and prognostic factors of Pneumocystis pneumonia with respiratory failure in non-HIV patients

  2024cites this paper
• Perianal infections in acute leukemia patients who received induction and consolidation chemotherapy

  2023cites this paper
• Pneumocystis jirovecii Pneumonia after Heart Transplantation: Two Case Reports and a Review of the Literature

  2023cites this paper
• Manejo en cuidado crítico de la toxicidad severa relacionada con la inmunoterapia en cáncer

  2023cites this paper
• Low- Versus Conventional-Dose Trimethoprim-Sulfamethoxazole Treatment for Pneumocystis Pneumonia in Non-Human Immunodeficiency Virus-Infected Patients: A Multi-Center, Retrospective Observational Cohort Study.

  2023cites this paper
• Management of Complications in Neuro-oncology Patients

  2023cites this paper
• Position statement on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies, part 3: precautions in situations of surgery, fever, and opportunistic infections

  2023cites this paper
• Pneumocystis pneumonia after allogeneic hematopoietic cell transplantation: A case-control study on epidemiology and risk factors on behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation.

  2023cites this paper
• Diagnostic efficiency of metagenomic next-generation sequencing for suspected infection in allogeneic hematopoietic stem cell transplantation recipients

  2023cites this paper
• Prophylaxis for Pneumocystis carinii pneumonia in non-Hodgkin’s lymphoma undergoing R-CHOP21 in China: a meta-analysis and cost-effectiveness analysis

  2023cites this paper
• Pneumocystis jirovecii diagnosed by next-generation sequencing of bronchoscopic alveolar lavage fluid: A case report and review of literature

  2023cites this paper
• Pneumocystis pneumonia in a patient with diabetes mellitus: A case report

  2023cites this paper
• Clinical features, risk factors, diagnosis, and treatment of trimethoprim-sulfamethoxazole-induced hypoglycemia

  2023influential citation
• Clinical features and diagnostic value of metagenomic next -generation sequencing in five cases of non-HIV related Pneumocystis jirovecii pneumonia in children

  2023cites this paper
• [Clinical characteristics and CT findings of Pneumocystis Jirovecii pneumonia in 46 cases with hematological diseases].

  2023cites this paper
• Pneumocystis jiroveci Pneumonia: A Review of Management in Human Immunodeficiency Virus (HIV) and Non-HIV Immunocompromised Patients

  2023cites this paper
• Low- versus conventional-dose trimethoprim-sulfamethoxazole for non-HIV PCP

  2023influential citation
• How to diagnose and treat a non-HIV patient with Pneumocystis jirovecii pneumonia (PCP)?

  2023cites this paper
• Current Concepts in the Diagnosis and Management of Pneumocystis Pneumonia in Solid Organ Transplantation.

  2023cites this paper
• Which trial do we need? Combination treatment of Pneumocystis jirovecii pneumonia in non-HIV infected patients.

  2023cites this paper
• How to use direct microscopy for diagnosing fungal infections.

  2023cites this paper
• Pneumocystis jirovecii and SARS-CoV-2 Coinfection as Presentation of X-linked Severe Combined Immunodeficiency

  2023cites this paper
• Efficacy of initial caspofungin plus trimethoprim/sulfamethoxazole for severe PCP in patients without human immunodeficiency virus infection

  2023cites this paper
• Pneumocystis jiroveci Pneumonia secondary to tyrosine kinase inhibitor with blinatumomab therapy: A case report.

  2022cites this paper
• Fungal Infections Other Than Invasive Aspergillosis in COVID-19 Patients

  2022cites this paper
• Non‐HIV‐infected patients with Pneumocystis pneumonia in the intensive care unit: A bicentric, retrospective study focused on predictive factors of in‐hospital mortality

  2022cites this paper
• Severe pulmonary co-infection with varicella-zoster virus, Pneumocystis jirovecii and Cytomegalovirus: a case report

  2022cites this paper
• Infectious Complications in Paediatric Haematopoetic Cell Transplantation for Acute Lymphoblastic Leukemia: Current Status

  2022cites this paper
• Trimethoprim-Sulfamethoxazole (Bactrim) Dose Optimization in Pneumocystis jirovecii Pneumonia (PCP) Management: A Systematic Review

  2022cites this paper
• Invasive Respiratory Fungal Infections in COVID-19 Critically Ill Patients

  2022cites this paper
• Bendamustine and pneumocystis pneumonia: A systematic review

  2022cites this paper
• Treatment With Reduced-Dose Trimethoprim-Sulfamethoxazole Is Effective in Mild to Moderate Pneumocystis jirovecii Pneumonia in Patients With Hematologic Malignancies

  2022cites this paper
• Prognostic factors and clinical efficacy of second-line treatments of Pneumocystis jirovecii pneumonia for non-HIV patients after first-line treatment failure

  2022cites this paper
• Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial

  2022cites this paper
• Metagenomic next-generation sequencing performed on blood samples for the early recognition of severe Pneumocystis pneumonia in critical hematological patients

  2022influential citation
• Targeted NGS-Based Analysis of Pneumocystis jirovecii Reveals Novel Genotypes

  2022cites this paper
• The medication for pneumocystis pneumonia with glucose-6-phosphate dehydrogenase deficiency patients

  2022cites this paper
• Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult kidney transplantation recipients: a real-world data study.

  2022cites this paper
• Metagenomic next-generation sequencing (mNGS) for diagnosis of invasive fungal infectious diseases: a narrative review

  2021cites this paper
• Pneumocystis pneumonia

  2021cites this paper
• Coronavirus Disease 2019–Associated Invasive Fungal Infection

  2021cites this paper
• A bi‐centric experience of extracorporeal carbon dioxide removal (ECCO2R) for acute hypercapnic respiratory failure following allogeneic hematopoietic stem cell transplantation

  2021cites this paper